A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST* study.A. Kapur, K.A. Latus, G. Davies, R.T. Dhawan, S. Eastick, P.H. Jarritt, G. Roussakis, M.C. Young, C. Anagnostopoulos, J. Bomanji, D.C. Costa, D.J. Pennell, E.M. Prvulovich, P.J. Ell, and S.R. Underwood *ROBUST is an acronym for the Royal Brompton and UCL Study of Thallium and Technetium. Comparison of Thallium-201 and Technetium-99m Myocardial Perfusion Tracers
Compare the technical and clinical performance of thallium-201 (Tl), methoxyisobutylisonitrile (MIBI), and tetrofosmin (Tf) in routine clinical practice.
Cardiolite
is a registered trademark of Bristol-Myers Squibb Medical Imaging,
Inc.
All three tracers perform well in clinical terms, with high sensitivity and specificity for angiographic stenosis and no differences in accuracy between tracers. References: 1. Kapur A, Latus KA, Davies G, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med. 2002:29;1608-1616. 2. MYOVIEW Prescribing Information. |
Order Your CopyContact your local GE Healthcare Imaging Specialist to obtain a copy of this study or call 1 800 654 0118.
|



